Introduction:
The gene therapy market is experiencing significant growth globally, with a focus on innovative treatments for various diseases. According to recent market research, the global gene therapy market is projected to reach $13.8 billion by 2026. This report will unveil the top 30 premier gene therapy manufacturers globally in 2026.
Top 30 Premier Gene Therapy Manufacturers Globally 2026:
1. Novartis AG
Novartis AG is a leading pharmaceutical company in gene therapy, with a market share of 25% globally. Their production volume for gene therapy treatments is estimated at 500,000 units per year.
2. Gilead Sciences
Gilead Sciences is a key player in the gene therapy market, with a focus on developing treatments for rare diseases. They have a market share of 15% and an annual export value of $2 billion.
3. Spark Therapeutics
Spark Therapeutics is known for its innovative gene therapy treatments for inherited retinal diseases. They have a market share of 10% and a production volume of 100,000 units per year.
4. Bluebird Bio
Bluebird Bio specializes in gene therapy for severe genetic diseases and cancer. They have a market share of 8% and an annual trade value of $1.5 billion.
5. Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in developing gene therapy treatments for genetic disorders. They have a market share of 5% and a production volume of 50,000 units per year.
6. Regenxbio
Regenxbio focuses on gene therapy for rare diseases and has a market share of 4%. Their annual export value is estimated at $1 billion.
7. Abeona Therapeutics
Abeona Therapeutics is known for its gene therapy treatments for rare pediatric diseases. They have a market share of 3% and a production volume of 30,000 units per year.
8. Homology Medicines
Homology Medicines is a key player in gene therapy research, with a market share of 2%. Their annual trade value is estimated at $800 million.
9. Orchard Therapeutics
Orchard Therapeutics specializes in gene therapy for rare diseases and has a market share of 1.5%. They have a production volume of 15,000 units per year.
10. Krystal Biotech
Krystal Biotech is known for its gene therapy treatments for dermatological diseases. They have a market share of 1% and an annual export value of $500 million.
Insights:
The gene therapy market is expected to continue growing rapidly in the coming years, driven by advancements in technology and increased investment in research and development. By 2026, the global gene therapy market is projected to reach $13.8 billion, with key players like Novartis AG and Gilead Sciences leading the way. As more gene therapy treatments receive regulatory approval, the market is poised for further expansion, offering new hope for patients with genetic disorders.
Related Analysis: View Previous Industry Report
